Group 1 - The core view of the report is that Zai Lab (02509) is expected to have EPS of 1.61, 0.88, and 0.55 RMB for the years 2025 to 2027, respectively, with a target price of 33.0 HKD, indicating a 41.6% upside potential from the current stock price [1] - The company has established a comprehensive end-to-end innovative drug development system, focusing on autoimmune and allergic diseases, with a pipeline covering four major therapeutic areas [2] - Zai Lab has one approved product and ten products in the research phase, with over 20 IND approvals, indicating a strong pipeline and development capability [2] Group 2 - The company has rapidly iterated its dual-antibody products in the autoimmune field, achieving three overseas collaborations within the year, demonstrating recognition from multinational corporations and biotech firms [3] - Potential catalysts for growth include the readout of Phase III data for QX005N, BLA submissions for QX002N, and the initiation of clinical trials for dual-antibody products both domestically and internationally [3]